(NASDAQ: ALDX) Aldeyra Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.59%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.81%.
Aldeyra Therapeutics's revenue in 2026 is $0.On average, 7 Wall Street analysts forecast ALDX's revenue for 2026 to be $1,398,242,356, with the lowest ALDX revenue forecast at $0, and the highest ALDX revenue forecast at $5,187,310,243. On average, 6 Wall Street analysts forecast ALDX's revenue for 2027 to be $689,047,560, with the lowest ALDX revenue forecast at $0, and the highest ALDX revenue forecast at $1,304,563,738.
In 2028, ALDX is forecast to generate $2,585,481,617 in revenue, with the lowest revenue forecast at $2,484,142,222 and the highest revenue forecast at $2,661,546,483.